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Abstract: The anticonvulsant carbamazepine is frequently used in the long-term therapy of epilepsy
and is a known substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. Carbamazepine
induces the metabolism of various drugs (including its own); on the other hand, its metabolism can
be affected by various CYP inhibitors and inducers. The aim of this work was to develop a physiolog-
ically based pharmacokinetic (PBPK) parent−metabolite model of carbamazepine and its metabolite
carbamazepine-10,11-epoxide, including carbamazepine autoinduction, to be applied for drug–drug
interaction (DDI) prediction. The model was developed in PK-Sim, using a total of 92 plasma
concentration−time profiles (dosing range 50–800 mg), as well as fractions excreted unchanged in
urine measurements. The carbamazepine model applies metabolism by CYP3A4 and CYP2C8 to
produce carbamazepine-10,11-epoxide, metabolism by CYP2B6 and UDP-glucuronosyltransferase
(UGT) 2B7 and glomerular filtration. The carbamazepine-10,11-epoxide model applies metabolism by
epoxide hydroxylase 1 (EPHX1) and glomerular filtration. Good DDI performance was demonstrated
by the prediction of carbamazepine DDIs with alprazolam, bupropion, erythromycin, efavirenz and
simvastatin, where 14/15 DDI AUClast ratios and 11/15 DDI Cmax ratios were within the prediction
success limits proposed by Guest et al. The thoroughly evaluated model will be freely available in
the Open Systems Pharmacology model repository.
Keywords: physiologically based pharmacokinetic (PBPK) modeling; carbamazepine; carbamazepine-
10,11-epoxide; drug–drug interactions (DDIs); cytochrome P450 3A4 (CYP3A4); cytochrome P450
2B6 (CYP2B6); induction
1. Introduction
The anticonvulsant drug carbamazepine is known to induce multiple metabolizing
enzymes. It is classified by the U.S. Food and Drug Administration (FDA) as a strong
inducer (area under the plasma concentration−time curve (AUC) decrease of victim drug
≥ 80%) of cytochromes P450 (CYP) 3A4 and CYP2B6 [1]. Furthermore, carbamazepine
itself is also metabolized by the respective enzymes [2], with metabolism via CYP3A4
to the pharmacologically active metabolite carbamazepine-10,11-epoxide as one of the
main routes of elimination [3]. As a result, carbamazepine induces its own—as well
as other drugs’—metabolism during multiple dose administration. Additionally, carba-
mazepine plasma levels can also be affected by enzyme inhibitors and inducers. There-
fore, the coadministration of carbamazepine with other drugs, i.e., sensitive CYP3A4 or
CYP2B6 substrates or perpetrators, can result in complex interaction patterns. Elevated
carbamazepine plasma concentrations, caused by CYP3A4 inhibition, as well as elevated
carbamazepine-10,11-epoxide plasma concentrations, caused by CYP3A4 induction, are
associated with carbamazepine-related adverse events, including nausea, vomiting, drowsi-
ness or mental confusion [4–6]. Additionally, as a strong enzyme inducer, carbamazepine
Pharmaceutics 2021, 13, 270. https://doi.org/10.3390/pharmaceutics13020270 https://www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2021, 13, 270 2 of 19
significantly reduces plasma concentrations of coadministered victim drugs. For the CYP3A4
substrate simvastatin and the CYP2B6 substrate bupropion, AUC decreases of 82% and
90% were observed if coadministered with carbamazepine [7,8], risking loss of efficacy of
those compounds.
As CYP3A4 is highly expressed in liver and intestine and metabolizes up to 50% of
all marketed drugs independent of the drug class [9], interactions with a broad spectrum
of substances are possible, for example with antiviral drugs (efavirenz) or antibiotics
(erythromycin). The drug–drug interaction (DDI) with efavirenz illustrates the complexity
of carbamazepine DDIs, as both compounds are CYP3A4 and CYP2B6 substrates as well as
inducers and therefore, mutually induce each other’s metabolism [10].
As carbamazepine plays a crucial role in the treatment of epilepsy (recommended as
first line treatment option by Cochrane [11] and included in the World Health Organization
(WHO) Model List of Essential Medicines [12]), surveillance and examination of its DDI
potential is important to ensure a safe drug therapy. The FDA recommends the use of
carbamazepine as CYP3A4 and CYP2B6 inducer in clinical drug–drug interaction studies
and it was applied in recent clinical trials, for example, with etonorgestrel, basimglurant or
bitopertin [13]. In this case, the physiologically based pharmacokinetic (PBPK) modeling
technique can come in as a helpful tool. With PBPK modeling, the pharmacokinetics
(PK) of carbamazepine can be quantitatively described and the model can be coupled
with other PBPK models to dynamically describe and predict DDIs. This modeling tech-
nique is recognized and recommended by the regulatory agencies FDA and the European
Medicines Agency (EMA) [14,15]. More than 60% of PBPK models submitted to the FDA
investigate DDIs. Several published studies investigate the DDI potential of carbamazepine
using a PBPK modeling approach [13,16–19]. While carbamazepine is typically used as an
inducer to investigate the interaction with a substrate, our study aims to provide a compre-
hensive overview on the pharmacokinetics of carbamazepine and its DDIs, investigating
carbamazepine not only as inducer but also as victim drug.
Hence, the aims of the current study were (1) to develop a parent−metabolite PBPK
model of carbamazepine and its main metabolite carbamazepine-10,11-epoxide, with
implementation of carbamazepine autoinduction and (2) to apply the developed model for
DDI predictions with carbamazepine as a perpetrator and victim drug.
The thoroughly evaluated model will be publicly available in the Open Systems
Pharmacology (OSP) repository and can be applied to investigate and predict CYP3A4 and
CYP2B6 DDIs. The Supplementary Materials to this paper will serve as a reference manual
with detailed documentation of the model development and performance.
2. Materials and Methods
2.1. Software
The PBPK model was developed with PK-Sim and MoBi (Open Systems Pharmacology
Suite 9.1, released under the GNU General Public License version 2 (GPLv2) license
by the Open Systems Pharmacology community, www.open-systems-pharmacology.org,
2020). Parameter optimization (Monte-Carlo and Levenberg-Marquardt algorithms) and
sensitivity analysis were performed with PK-Sim. Clinical study data from literature
were digitized with Engauge Digitizer Version 10.12 (M. Mitchell [20], 2019) according
to guidelines by Wojtyniak et al. [21]. Pharmacokinetic parameters were calculated and
plots were created with R 3.6.2 (The R Foundation for Statistical Computing, Vienna,
Austria, 2019).
2.2. Clinical Data
Plasma and saliva concentration−time profiles and fraction excreted (fe) unchanged
in urine measurements of carbamazepine and carbamazepine-10,11-epoxide were collected
and digitized from published clinical studies. Studies were selected to cover the adminis-
tration of carbamazepine (1) over a broad dosing range, (2) in single- and multiple-dosing
regimens and (3) for different carbamazepine formulations. Clinical studies investigating
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the oral administration of the metabolite carbamazepine-10,11-epoxide were also included.
Studies were preferred if they were conducted with healthy participants without comedica-
tion and if frequent as well as late sampling data was provided.
The digitized clinical studies were split into a model building (training) dataset and
a model evaluation (test) dataset. The studies for the training dataset were selected to
inform the implemented pharmacokinetic processes by covering a broad dosing range,
single- and multiple-dose studies, the application of different carbamazepine formulations,
and information on saliva concentrations and urinary excretion of carbamazepine as well
as plasma concentrations and urinary excretion of the metabolite carbamazepine-10,11-
epoxide. An overview of all utilized clinical studies and their assignment to training or test
dataset is documented in Table S1 of the Supplementary Materials.
2.3. Model Building
The modeling process was initiated with a literature search for physicochemical pa-
rameters and information on absorption, distribution, metabolism and excretion (ADME)
processes. During model development, different reported parameter values and the im-
pact of different ADME processes were tested. An overview of the ADME processes of
carbamazepine is provided in the Supplementary Materials and corresponding literature
parameters are listed in Table 1.
For simulations, virtual mean individuals were generated based on age, sex, ethnicity,
body weight, and height as reported in the respective study protocols. If no information
was provided, a 30-year-old, male, European individual with mean body weight and height
characteristics from the PK-Sim population database was created. The PK-Sim expression
database [22] was used to define the relative expression of relevant metabolizing enzymes
in the different organs of the body. Model parameters that could not be described using
information from literature were estimated by fitting the model to the observed data of the
whole training dataset.
An overview of essential parameters needed to build a PBPK model, the whole-body
PBPK model structure and implemented elimination processes are illustrated in Figure 1.
Elimination processes for carbamazepine include (1) metabolism by CYP3A4 and
CYP2C8 to carbamazepine-10,11-epoxide, (2) metabolism by CYP3A4, CYP2B6 and UGT2B7
as well as hepatic clearance to cover further metabolic processes, (3) autoinduction of
CYP3A4 and CYP2B6 and (4) passive glomerular filtration with tubular reabsorption [23].
The carbamazepine-10,11-epoxide metabolite model includes (1) metabolism by epoxide
hydroxylase 1 (EPHX1) [24,25] and (2) renal elimination via passive glomerular filtration
with tubular reabsorption.
Development of the parent−metabolite PBPK model was accomplished in a stepwise
procedure. First, a model for the metabolite carbamazepine-10,11-epoxide was developed,
based on three clinical studies that administered carbamazepine-10,11-epoxide. Metabolism
by EPHX1 was implemented as a first-order clearance process according to Equation (1):
v = [E]∗CLspec∗S (1)
where [E] = enzyme concentration, CLspec = specific enzymatic clearance and S = substrate
amount.
Passive glomerular filtration with reabsorption was described using a glomerular
filtration rate (GFR) fraction < 1. The metabolite carbamazepine-10,11-epoxide model
was subsequently combined with the parent carbamazepine model and the implemented
parameter values were refined during development of the parent−metabolite model using
the whole training dataset.
Metabolic pathways of carbamazepine were implemented using Michaelis−Menten
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where [E] = enzyme concentration, kcat = catalytic rate constant, [S] = substrate concentra-
tion and Km = Michaelis−Menten constant.
Induction of CYP3A4, CYP2B6 and EPHX1 was implemented using a maximum effect
(Emax) model, as described in the Supplementary Materials Section 1.5. To inform the
optimization of CYP3A4 induction, the carbamazepine-alprazolam DDI study was added
to the training dataset. Renal clearance of carbamazepine, consisting of passive glomerular
filtration with tubular reabsorption, was modeled using an estimated GFR fraction < 1.
Oral dosage forms of carbamazepine in the modeled clinical studies include solu-
tions, suspensions, immediate release tablets and extended release tablets or capsules. To
simulate solutions and suspensions, carbamazepine was modeled as a dissolved drug.
The dissolution kinetics of the other formulations were described using Weibull functions.
Different parameters were estimated for fasted or fed state, as Levy et al. and McLean et al.
observed an increased carbamazepine absorption for ingestion of different carbamazepine
formulations with food [26,27].
2.4. PBPK Model Evaluation
Model performance was evaluated (1) by comparing the predicted plasma
concentration−time profiles to observed profiles and (2) by comparing predicted plasma
concentration values to the corresponding observed values in goodness-of-fit plots, as well
as (3) by comparing predicted with observed area under the plasma concentration−time
curve (AUC) and maximum plasma concentration (Cmax) values. AUC values were calcu-
lated from the time of drug administration to the time of the last concentration measurement
(AUClast). Predictions were considered successful if they did not deviate more than 2-fold
from observed values.
For a quantitative description of the model performance, the mean relative deviation
(MRD) of predicted plasma concentrations and the geometric mean fold error (GMFE) of
predicted AUClast and Cmax values were calculated as described in the Supplementary Ma-
terials. We considered MRD and GMFE values ≤ 2 as adequate model performance metrics.
2.5. DDI Modeling
In addition to the previously described methods for PBPK model evaluation, the
carbamazepine model was challenged by prediction of DDIs, with carbamazepine as
CYP3A4 and CYP2B6 victim or perpetrator drug.
Clinical DDI studies with erythromycin, alprazolam, simvastatin, bupropion and
efavirenz were available and used for DDI modeling. The previously developed PBPK
models of erythromycin, alprazolam and efavirenz were downloaded from the OSP reposi-
tory on GitHub (https://github.com/Open-Systems-Pharmacology [28–30]). The bupro-
pion [31] and simvastatin [32] models were developed in our working group.
The parameters describing the induction of CYP3A4 and CYP2B6 by carbamazepine
were already introduced during carbamazepine model building, as the compound induces
its own metabolism. The mathematical implementation of the induction processes is de-
scribed in Section 1.5 in the Supplementary Materials. The carbamazepine-alprazolam DDI
study was used in the training dataset to inform the parametrization of the carbamazepine
CYP3A4 induction. All other DDIs were purely predictive.
The DDI performance of all models except the efavirenz model (CYP2B6) was eval-
uated previously [28–32]. Therefore, all relevant interaction parameters were already
implemented in the models and adopted in this project. The mathematical implementa-
tion of (1) the mechanism-based CYP3A4 inhibition by erythromycin, (2) the induction of
CYP3A4 by efavirenz, (3) the induction of CYP2B6 by efavirenz and (4) the competitive
inhibition of CYP3A4 by simvastatin are described in the Supplementary Materials. The
drug-dependent parameters and interaction parameters of the previously developed mod-
els applied for carbamazepine DDI predictions are reproduced in Tables S6, S12, S15, S18
and S21 in the Supplementary Materials.
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The performance of the efavirenz model as a CYP2B6 substrate and inducer was
evaluated prior to DDI modeling with carbamazepine, using bupropion and rifampicin as
CYP2B6 substrate and inducer, respectively. Based on this evaluation, the efavirenz model
parameters were readjusted, which is further described in the Supplementary Materials.
2.6. DDI Model Evaluation
The DDI performance was assessed by comparison of predicted to observed victim
drug plasma concentration−time profiles without and with coadministration of the perpe-
trator drug. Additionally, predicted DDI AUClast ratios (Equation (3)) and DDI Cmax ratios
(Equation (4)) were compared to the respective observed ratios.
DDI AUClast ratio =
AUClast victim drug during coadministration
AUClast victim drug alone
(3)
DDI Cmax ratio =
Cmax victim drug during coadministration
Cmax victim drug alone
(4)
As stated by Guest et al. [33], allowing up to 2-fold deviation of predicted to observed
DDI ratios is not appropriate to assess the success of DDI predictions. For observed
DDI ratios of 1 (no interaction), the 2-fold deviation would allow predicted DDI ratios
between 0.5 (induction) and 2 (weak to moderate inhibition), which could overstate the
DDI performance for weak interactions. Therefore, the prediction success limits proposed
by Guest et al. [33] were used to evaluate the DDI predictions, accepting 20% deviation for
observed DDI ratios approaching 1.
For each DDI, GMFEs of the predicted DDI AUClast ratios and DDI Cmax ratios were
calculated, as described in the Supplementary Materials.
Figure 1. Schematic representation of the PBPK modeling workflow. (a) PBPK modeling requires system- and drug-
dependent parameters, describing the anatomical and physiological characteristics of the individual and the properties of
the simulated compound, respectively. Information on the study protocol of the described clinical study is relevant as well,
e.g., formulation and administration of the simulated compound. (b) The PBPK model consists of multiple compartments,
representing organs of the body, which are connected via the arterial and venous blood flows. (c) The final structure of the
carbamazepine parent−metabolite PBPK model. (d) Overview of the modeled DDIs. Drawings by Servier, licensed under
CC BY 3.0 [34]. CYP: cytochrome P450, EPHX1: epoxide hydroxylase 1, Kd: dissociation constant, Km: Michaelis−Menten
constant, pKa: acid dissociation constant, UGT: UDP-glucuronosyltransferase, Vmax: maximum velocity.
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3. Results
3.1. PBPK Model Building
The parent−metabolite PBPK model of carbamazepine and carbamazepine-10,11-
epoxide was built and evaluated using 40 clinical studies of oral administration, covering a
broad dosing range (50–800 mg), different formulations as well as single- and multiple-dose
regimens. In three of the included studies, the metabolite carbamazepine-10,11-epoxide
was administered. In total, 58 and 34 plasma concentration−time profiles, and 4 and
5 fraction excreted unchanged in urine profiles, of carbamazepine and carbamazepine-
10,11-epoxide were used, respectively. Additionally, 3 saliva concentration−time profiles
were available for carbamazepine. All utilized clinical studies are listed in Table S1 of the
Supplementary Materials.
Metabolism of carbamazepine by CYP2C8, CYP2B6 and UGT2B7 was described using
Km and kcat values from literature. Two metabolic processes by CYP3A4 were implemented,
as carbamazepine is metabolized by CYP3A4 to carbamazepine-10,11-epoxide as well as to
hydroxylated metabolites [35]. For both reactions, Km values were taken from literature,
while kcat values were optimized.
A half-maximal effective concentration EC50 = 20.0 µM (mean value calculated from
literature values) was applied to describe the CYP3A4 induction. Although literature values
for CYP2B6 EC50 were reported, the same EC50 = 20.0 µM was applied to describe the
CYP2B6 induction, assuming that induction of both enzymes by carbamazepine is mediated
via activation of the same nuclear receptor (constitutive androstane receptor [CAR]) [36].
The associated Emax values were optimized. Induction of EPHX1 was implemented as
well, based on reports of an increase in carbamazepine-10,11-epoxide clearance during
chronic carbamazepine treatment [37]. As no information on EC50 or Emax for EPHX1 was
available, EC50 = 20.0 µM was used, assuming induction via activation of CAR as well, and
Emax was optimized.
All implemented metabolic processes are summarized in Figure 1c. Drug-dependent
parameters of carbamazepine and carbamazepine-10,11-epoxide are listed in Table 1, details
on the distribution and localization of the implemented enzymes are provided in Table S45
of the Supplementary Materials.
Table 1. Drug-dependent parameters of carbamazepine and carbamazepine-10,11-epoxide.
Parameter Unit Model Literature Reference
Carbamazepine
Molecular weight g/mol 236.27 (Lit) 236.27 [38]
Lipophilicity Log Units 2.00 (Fit) 1.45; 2.1; 2.45; 2.77 [38–40]
Solubility (FaHIF) µg/mL 336 (Lit) 170; 283; 306; 336 [41–44]
Fraction unbound % 25 (Lit) 21; 24; 25 [45–48]
Km (CYP3A4)→ CBZ-E µM 248 (Lit) 119; 248; 442; 630 [2,49–51]
kcat (CYP3A4)→ CBZ-E 1/min 0.75 (Fit) 1.17; 1.7; 4.87; 5.3 b [2,49–51]
Km (CYP2C8)→ CBZ-E µM 757 (Lit) 757 [50]
kcat (CYP2C8)→ CBZ-E 1/min 0.67 (Lit) 0.67 b [50]
Km (CYP3A4) µM 282 (Lit) 282 [35]
kcat (CYP3A4) 1/min 0.20 (Fit) 0.16 b [35]
Km (CYP2B6) µM 420 (Lit) 420 [35]
kcat (CYP2B6) 1/min 0.43 (Lit) 0.43 b [35]
Km (UGT2B7) µM 214 (Lit) 214 [52]
kcat (UGT2B7) 1/min 9.53 × 10−3 (Lit) 9.53 × 10−3 c [52]
CLhep 1/min 0.02 (Fit) - -
GFR fraction - 0.03 (Fit) - -
EC50 (CYP3A4) µM 20.00 a (Lit) 4.3–137 [53–60]
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Table 1. Cont.
Parameter Unit Model Literature Reference
Carbamazepine
Emax (CYP3A4) - 6.00 (Fit) 1.9–23 [53–60]
EC50 (CYP2B6) µM 20.00 a (Asm) 22–145 [60–62]
Emax (CYP2B6) - 17.00 (Fit) 3.1–21.5 [60–62]
EC50 (EPHX1) µM 20.00 a (Asm) - -
Emax (EPHX1) - 3.25 (Fit) - -
Intestinal permeability cm/s 4.3 × 10−4 (Lit) 4.3 × 10−4 [63]
Partition coefficients - Rodgers and Rowlands [64,65]
Cellular permeabilities cm/s PK-Sim Standard [66]
Carbamazepine-10,11-epoxide
Molecular weight g/mol 252.27 (Lit) 252.27 [67]
Lipophilicity Log Units 1.00 (Fit) 1.58; 1.97 [67]
Solubility µg/mL 1340 (Lit) 1340 [67]
Fraction unbound % 51.8 (Lit) 46.8; 49.0; 47.0; 51.8; 50.0 [68]
CLspec (EPHX1) 1/min 0.01 (Fit) - -
GFR fraction - 0.21 (Fit) - -
Intestinal permeability cm/s 5.0 × 10−3 (Fit) - -
Partition coefficients - Rodgers and Rowlands [64,65]
Cellular permeabilities cm/s PK-Sim Standard [66]
Asm: assumption, CBZ-E: carbamazepine-10,11-epoxide, CLhep: hepatic clearance, CLspec: specific clearance, CYP: cytochrome P450, GFR:
glomerular filtration rate, EC50: half maximal effective concentration, Emax: maximum effect, EPHX1: epoxide hydroxylase 1, FaHIF: fasted
human intestinal fluid, Fit: fitted in parameter optimization, Km: Michaelis−Menten constant, kcat: catalytic rate constant, Lit: literature,
UGT: UDP-glucuronosyltransferase, Vmax: maximum reaction velocity. a mean of literature values of EC50 (CYP3A4), assumed for all EC50
values. b kcat values calculated within PK-Sim from Vmax/recombinant enzyme. c kcat value calculated within PK-Sim from Vmax = 0.79
pmol/min/microsomal protein, derived from in vitro assays in microsomes, assuming a microsomal UGT2B7 content of 82.9 pmol/mg
microsomal protein [69]; kcat = Vmax/UGT2B7 content microsomes.
Figure 2 shows exemplary predictions of plasma concentration−time profiles com-
pared to observed clinical data. Predicted compared to observed plasma concentration−time
profiles of all studies are shown in the Supplementary Materials on a linear and semi-
logarithmic scale.
Plasma concentration goodness-of-fit plots along with MRD values for all analyzed
studies are provided in the Supplementary Materials. In total, 94% and 69% of all carba-
mazepine and carbamazepine-10,11-epoxide plasma concentrations lie within the 2-fold
acceptance limits, with overall MRD values of 1.38 and 1.76, respectively. Figure 3 shows
predicted compared to observed AUClast and Cmax values. Low overall GMFEs of 1.20 and
1.57 for carbamazepine and carbamazepine-10,11-epoxide AUClast values, as well as 1.24
and 1.65 for carbamazepine and carbamazepine-10,11-epoxide Cmax values, respectively,
demonstrate a good model performance. Table S4 lists all AUClast and Cmax values with
the corresponding GMFEs.
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Figure 2. Model predictions of carbamazepine (dark blue: plasma, light blue: saliva) and carbamazepine-10,11-epoxide
(green) concentration−time profiles of exemplary studies after (a–e) single- and (f–i) multiple-dose administration of
different carbamazepine formulations [70–78] in comparison to observed data. Observed data are shown as dots ± SD (if
available), simulations are shown as solid lines. Detailed information about the study protocols and model simulations of
all clinical studies used to evaluate the carbamazepine model performance are provided in the Supplementary Materials.
bid: twice daily, cap: capsule, D: day, n: number of subjects, qd: once daily, sd: single dose, sol: solution, susp: suspension,
tab: tablet, tab*: tablet with concomitant food intake, te: test dataset, tr: training dataset, XR: extended release.
Sensitivity analysis of a simulation of 400 mg three times daily orally administered
carbamazepine with a parameter perturbation of 1000% and a sensitivity threshold of 0.5
revealed that the carbamazepine AUC is mainly sensitive to the carbamazepine fraction
unbound in plasma (literature), while the carbamazepine-10,11-epoxide AUC is sensitive
to carbamazepine-10,11-epoxide fraction unbound in plasma (literature), EPHX1 clearance
of carbamazepine-10,11-epoxide (optimized), Km and kcat of carbamazepine CYP3A4
metabolism to carbamazepine-10,11-epoxide (literature and optimized, respectively) and
carbamazepine EPHX1 Emax (optimized). The full quantitative results of the sensitivity
analysis of all tested parameters are documented in the Supplementary Materials.
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Figure 3. Performance of the carbamazepine parent−metabolite PBPK model. Predicted compared to observed (a) AUClast
values and (b) Cmax values of carbamazepine and carbamazepine-10,11-epoxide of all analyzed studies. The line of identity
is shown as solid line; 1.25-fold deviation is shown as dotted lines; 2-fold deviation is shown as dashed lines. AUClast: area
under the plasma concentration−time curve from dosing to the last concentration measurement, Cmax: maximum plasma
concentration, te: test dataset, tr: training dataset.
3.2. DDI Modeling
A total number of seven DDI studies, providing eight victim drug plasma
concentration−time profiles and seven metabolite plasma concentration−time profiles,
were used to evaluate the DDI performance of the carbamazepine parent−metabolite PBPK
model. Those include studies with CYP3A4 victim drugs (alprazolam and simvastatin), a
CYP3A4 inhibitor (erythromycin), a CYP2B6 victim drug (bupropion) as well as a CYP3A4
and CYP2B6 victim and perpetrator drug (efavirenz). The carbamazepine DDI network is
illustrated in Figure 1d.
The DDI potential of carbamazepine as CYP3A4 substrate was assessed using three
DDI studies with erythromycin as mechanism-based CYP3A4 inhibitor and substrate. In
two studies a single dose of carbamazepine was applied after pretreatment with multiple
doses of erythromycin [4,79]. In the third study, patients were pretreated with multiple
doses of carbamazepine before coadministration of multiple doses of erythromycin [80],
resulting in significant induction of CYP3A4 before the administration of the CYP3A4
inhibitor erythromycin.
The DDI potential of carbamazepine as CYP3A4 and CYP2B6 inducer was assessed
using DDI studies with alprazolam and simvastatin as CYP3A4 and bupropion as CYP2B6
victim drugs. In those studies, pretreatment with multiple doses of carbamazepine was
initiated to ensure significant enzyme induction before a single oral dose of the respective
victim drugs was administered [7,8,81]. In the utilized efavirenz−carbamazepine DDI
study, both compounds were administered in multiple oral dose regimens. The effect
of drug coadministration was examined for each drug. Information on all utilized DDI
studies along with detailed study protocols, demographics and references is provided in
Tables S13, S16, S19, S22 and S24 in the Supplementary Materials.
The DDI performance of the carbamazepine model with carbamazepine as victim
or perpetrator drug is shown in Figures 4 and 5, respectively. Plots show predicted
victim drug plasma concentration−time profiles, with and without coadministration of the
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perpetrator drug, compared to observed data. Predicted compared to observed plasma
concentration−time profiles of all DDI studies are also depicted in the Supplementary
Materials on a semi-logarithmic and linear scale.
Predicted compared to observed DDI AUClast and DDI Cmax ratios are visualized
in Figure 6 and are listed along with the corresponding GMFE values in Section 5 of the
Supplementary Materials. 14/15 DDI AUClast ratios and 11/15 DDI Cmax ratios were
within the prediction success limits proposed by Guest et al., with low overall GMFEs of
1.26 and 1.30 for all predicted DDI AUClast and Cmax ratios, respectively.
Figure 4. Victim drug plasma concentration−time profiles of the modeled drug–drug interactions with carbamazepine
as victim drug (first row: carbamazepine, second row: metabolite carbamazepine-10,11-epoxide). Predictions of the
victim drug plasma concentrations during the erythromycin−carbamazepine DDI (a) without and (b) with carbamazepine
pretreatment [79,80] and (c) the efavirenz−carbamazepine DDI [8] are shown in comparison to observed data. Observed
data are shown as dots ± SD (if available); predictions are shown as solid lines. Details on the study protocols and model
simulations of all investigated DDI studies are provided in the Supplementary Materials. md: multiple dose, n: number of
individuals, sd: single dose, tab: tablet, tab*: tablet with concomitant food intake.
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Figure 5. Victim drug plasma concentration−time profiles of the modeled drug–drug interactions with carbamazepine as
perpetrator drug. Predictions of the victim drug plasma concentrations during the (a) carbamazepine−alprazolam DDI [81],
(b) carbamazepine−simvastatin DDI [7] (c) carbamazepine−bupropion DDI [8] and (d) carbamazepine−efavirenz DDI [10]
are shown in comparison to observed data. Observed data are shown as dots ± SD (if available); predictions are shown
as solid lines. Details on the study protocols and model simulations of all investigated DDI studies are provided in the
Supplementary Materials. md: multiple dose, n: number of individuals, sd: single dose, tab: tablet.
Pharmaceutics 2021, 13, 270 12 of 19
Figure 6. DDI performance of the carbamazepine parent−metabolite PBPK model. Predicted compared to observed (a) DDI
AUClast ratios and (b) DDI Cmax ratios of all analyzed DDI studies. Dots represent the victim drug; triangles, diamonds and
squares of the same color represent respective metabolites. The line of identity is shown as a straight solid line; the curved
solid lines mark the prediction success limits proposed by Guest et al. [33]. A 1.25-fold deviation is shown as dotted lines;
2-fold deviation is shown as dashed lines. Details on the study protocols and all individual DDI AUClast and DDI Cmax
ratios are provided in the Supplementary Materials. AUClast: area under the plasma concentration−time curve from dosing
to the last concentration measurement, Cmax: maximum plasma concentration, DDI: drug–drug interaction, m: number
of studies.
4. Discussion
In the presented study, a whole-body parent−metabolite PBPK model of car-
bamazepine and its main metabolite carbamazepine-10,11-epoxide was successfully
established. The model adequately describes and predicts the plasma (and saliva)
concentration−time profiles and the urinary excretion of carbamazepine and its main
metabolite over a broad carbamazepine dosing range (50–800 mg) for oral administration
of different formulations in single- and multiple-dose regimens, with and without concomi-
tant food intake. The good model performance has been shown by a thorough evaluation
of the PBPK model. Furthermore, the model was successfully applied for DDI simulations
and predictions with erythromycin, alprazolam, simvastatin, bupropion and efavirenz.
The developed PBPK model includes a detailed description of carbamazepine
metabolism via CYP3A4, CYP2C8, CYP2B6 and UGT2B7 and of carbamazepine-10,11-
epoxide metabolism via EPHX1, including carbamazepine (auto-)induction of CYP3A4,
CYP2B6 and EPHX1. Relevant ADME processes were predominantly parametrized using
literature values. Only very few parameters were optimized, including lipophilicity, GFR
fraction of parent and metabolite, CYP3A4 kcat values, EPHX1 clearance as well as Emax
values of the induction processes. The lipophilicity of a compound is used to calculate
the organ permeabilities in PK-Sim. As logP is used as a surrogate input parameter for
lipophilicity and might not fully describe the permeability properties of a compound, the
lipophilicity value was optimized. GFR fraction was optimized to a value < 1, as passive
reabsorption of carbamazepine along the renal tubule after glomerular filtration due to its
high permeability is described in literature [23]. The CYP3A4 kcat values were optimized, to
correctly describe the plasma concentrations of the metabolite, while the EPHX1 clearance
had to be optimized, as no information was available in the literature.
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Predicted plasma concentration−time profiles of carbamazepine-10,11-epoxide showed
discrepancies in comparison to observed data for some studies (Figure 2 and Figures S2–S5).
The model tends to overpredict the data, while the observed plasma concentration−time
profiles exhibit high variability of unknown origin. We reviewed the implemented for-
mation, distribution and degradation processes of carbamazepine-10,11-epoxide, to
understand the deviation between observations and model predictions. The formation
of carbamazepine-10,11-epoxide is mediated by carbamazepine CYP3A4 and CYP2C8
metabolism, evaluated during DDI predictions. The good DDI performance of the
parent−metabolite model indicates a reasonable implementation of the formation of
carbamazepine-10,11-epoxide. As carbamazepine-10,11-epoxide is almost completely me-
tabolized via EPHX1 [24,82], and high interindividual variability of EPHX1 activity was
presumed [83], the variability observed in clinical study data might be caused by variability
in EPHX1 metabolism. As no information on EPHX1 activity is provided in the reviewed
studies, EPHX1 variability could not be reasonably reflected in the model. Furthermore,
P-glycoprotein (P-gp) is discussed as carbamazepine-10,11-epoxide transporter [84]. Due
to lack of conclusive evidence and studies parametrizing this transport, P-gp transport was
not implemented. Overall, the carbamazepine-10,11-epoxide PBPK model was carefully
developed, including studies of direct oral administration of carbamazepine-10,11-epoxide,
and the model evaluation, including overall GMFE values of 1.57 and 1.65 for AUClast and
Cmax, for carbamazepine-10,11-epoxide yet indicates an adequate model performance.
The observed concentrations of carbamazepine in saliva are also well captured, demon-
strating the good description of carbamazepine distribution. Correct description of saliva
concentrations can be useful for further model applications, as saliva is used as a surrogate
for plasma sampling in clinical practice (ratio saliva:plasma = 1:4, reflecting the free fraction
of carbamazepine [48]).
With regard to drug transporters, P-gp is also discussed as a carbamazepine trans-
porter, but without conclusive evidence in the literature [84–88]. P-gp would impact the
carbamazepine pharmacokinetics by limiting the absorption from the gastrointestinal tract,
hindering the penetration into the central nervous system and increasing the urinary excre-
tion [89]. How strong this impact would be, with a drug as lipophilic as carbamazepine
(logP of 1.45–2.77 [38–40]), is not clear. As there is conflicting information, and in the
absence of in vitro studies of carbamazepine transport by P-gp in the literature, transport
via P-gp was not implemented into the model. However, the model successfully describes
the absorption of low (50 mg) and high (800 mg) carbamazepine doses as well as the urinary
excretion of the unchanged drug.
As carbamazepine induces its own metabolism by activation of nuclear receptors
resulting in an increased CYP3A4 and CYP2B6 expression, the pharmacokinetics of carba-
mazepine are quite complex. CYP enzyme induction is highly variable, with reported EC50
and Emax values ranging between 4.3–108 µM and 1.9–24.7 for CYP3A4 and 22–145 µM
and 3.1–29.1 for CYP2B6 induction, respectively. The mean EC50 = 20 µM of all included
CYP3A4 induction studies was selected for all implemented induction processes, assuming
that induction of those enzymes is the result of carbamazepine activation of the CAR
receptor [36]. The incorporated CYP3A4 induction was evaluated by prediction of mul-
tiple dose carbamazepine studies from the test dataset, as well as by prediction of the
carbamazepine−simvastatin DDI, showing a good DDI performance with a predicted DDI
AUClast ratio of 0.20 compared to the observed ratio of 0.26.
The implementation of CYP3A4 metabolism of carbamazepine was further evaluated
via the prediction of three erythromycin−carbamazepine DDI studies. For single dose
carbamazepine administration (negligible CYP3A4 induction) the effect on carbamazepine
is very well described with predicted compared to observed DDI AUClast ratios of 1.22 and
1.14, respectively (study by Barzaghi et al. [79]) and 1.17 and 1.18, respectively (study by
Wong et al. [4]). For multiple dose carbamazepine administration (considerable CYP3A4
induction) the effect on carbamazepine is also well described, with predicted compared to
observed DDI AUClast ratios of 1.18 and 1.03, respectively (study by Miles et al. [80]). In all
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cases, the effect of erythromycin on carbamazepine-10,11-epoxide plasma concentrations is
well captured, with predicted compared to observed DDI AUClast ratios of 0.60 and 0.61,
respectively (study by Barzaghi et al. [79]) and 0.71 and 0.76, respectively (study by Miles
et al. [80]). As carbamazepine-10,11-epoxide is mainly formed by CYP3A4 metabolism, it
can be assumed that the fraction of carbamazepine metabolized via CYP3A4, and the effect
of erythromycin on carbamazepine CYP3A4 metabolism, are accurately implemented in
the applied models.
The Emax for CYP2B6 induction was identified during the carbamazepine model pa-
rameter identification and the description of CYP2B6 induction in the model was evaluated
by prediction of the carbamazepine-bupropion and the efavirenz−carbamazepine DDIs.
The simulated effect of carbamazepine on bupropion is underpredicted, showing predicted
compared to observed DDI AUClast ratios of 0.13 and 0.07, respectively. In this study,
bupropion was administered to 12 patients with major affective disorders, who previously
had chronic carbamazepine monotherapy and to 17 healthy individuals as control group.
Carbamazepine doses for each patient as well as duration of their carbamazepine therapy
were not provided in the study report. Furthermore, in the respective study, the phar-
macokinetics of bupropion with and without carbamazepine coadministration were not
investigated in a cross-over fashion, and therefore the results might be significantly influ-
enced by the CYP2B6 genotypes of the two different study populations, because CYP2B6
polymorphism is a major determinant of bupropion pharmacokinetics.
The efavirenz−carbamazepine DDI was well described, with predicted compared
to observed DDI AUClast ratios of 0.84 and 0.75 for carbamazepine, and 1.16 and 1.06 for
carbamazepine-10,11-epoxide, respectively, for the effect of efavirenz on carbamazepine.
The interaction between efavirenz and carbamazepine is quite complex, as both compounds
are substrates and well as inducers of CYP3A4 and CYP2B6, while CYP3A4 metabolism
plays only a minor role for efavirenz [90]. Regarding the effect of carbamazepine on
efavirenz, the effect is also well described with predicted compared to observed DDI
AUClast ratios of 0.46 and 0.66, respectively. The correct prediction of the impact of a
perpetrator drug on the pharmacokinetics of a victim drug indicates that the perpetrator
model adequately describes the drug concentrations at the sites of interaction and that the
victim drug model simulates the right amount of drug eliminated via the affected pathway.
The presented efavirenz−carbamazepine DDI example illustrates the value and power of
PBPK DDI modeling, which allows us to dynamically compute the changes of perpetrator
and victim drug plasma and tissue concentrations, as well as drug concentration-dependent
induction of enzyme expression over time.
Several published studies investigate the pharmacokinetics of carbamazepine using
PBPK modeling, (1) to predict the pharmacokinetics of carbamazepine in the pediatric
population [91], (2) to describe gastrointestinal absorption of different carbamazepine
formulations [92], (3) to investigate the DDI with levonorgestrel [93] and (4) to investigate
the DDI performance of victim drug models with carbamazepine as enzyme inducer [15–18]
using the default Simcyp parent−metabolite PBPK template model of carbamazepine and
carbamazepine-10,11-epoxide [19].
In contrast to the previously published models, we used a large set of clinical data for
model development (58 and 34 plasma profiles, as well as 4 and 5 fraction excreted in urine
profiles, of carbamazepine and carbamazepine-10,11-epoxide, respectively). Additionally,
our model provides an extensive overview on carbamazepine pharmacokinetics, including
(1) the description of the metabolite carbamazepine-10,11-epoxide, (2) a detailed and mech-
anistic implementation of carbamazepine metabolism and autoinduction using in vitro
literature parameter values, (3) the ability to describe different formulations applied in
fasted or fed state and (4) thorough evaluation of metabolic and inductive processes in
DDI simulations with CYP3A4 and CYP2B6 victim and perpetrator drugs. Carbamazepine
is typically investigated as enzyme inducer. The presented study also investigated car-
bamazepine as a victim drug–a scenario which should not be neglected as illustrated
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in the complex interaction with efavirenz, where both compounds mutually influence
their pharmacokinetics.
The presented carbamazepine parent−metabolite PBPK model can be applied to
investigate and predict DDI scenarios with carbamazepine as CYP3A4 and CYP2B6 inducer
and substrate. Such predictions can be used to support the design of clinical DDI studies
of new drugs. As carbamazepine is prescribed as a long-term treatment of epilepsy, at
times it might be coadministered with interacting drugs in clinical practice. In this case,
the presented model could be applied to guide dose recommendations. As carbamazepine
is a known inducer of further enzymes and transporters, e.g., CYP2C9 [1] or P-gp [94],
future applications of the model could include the implementation of those inductions, as
soon as PBPK models of sensitive substrates and the corresponding clinical DDI studies
become available.
5. Conclusions
A comprehensive whole-body parent−metabolite PBPK model of carbamazepine and
its main metabolite carbamazepine-10,11-epoxide was successfully established. The model
includes metabolism of carbamazepine by CYP3A4, CYP2C8, CYP2B6 and UGT2B7; all
Michaelis−Menten constants and most of the metabolic rate constants for these reactions
were implemented using published in vitro values. In addition, it incorporates the (auto-
)induction of CYP3A4, CYP2B6 and the carbamazepine-10,11-epoxide hydroxylase EPHX1
by carbamazepine. The model can be applied to predict plasma concentration−time
profiles of carbamazepine and carbamazepine-10,11-epoxide administered in single- and
multiple-dose regimens or different formulations. Furthermore, the presented model
was thoroughly challenged and evaluated by prediction of DDIs in an extensive DDI
network with five perpetrator and victim drugs and different study protocols. Noteworthy
is the good prediction of the complex efavirenz−carbamazepine DDI with its mutual
induction of CYP3A4 and CYP2B6. The good DDI performance is fully documented in the
Supplementary Materials and the model is considered qualified for CYP3A4 and CYP2B6
DDI prediction. The modeling files will be shared with the scientific community in the
Open Systems Pharmacology model repository (www.open-systems-pharmacology.org).
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-4
923/13/2/270/s1: Comprehensive reference manual, providing documentation of the complete
model performance assessment. Section 1: Physiologically based pharmacokinetic (PBPK) modeling.
Section 2: Carbamazepine, Section 3: Efavirenz. Section 4: Efavirenz drug-gene interactions (DGI).
Section 5: Carbamazepine drug-drug interactions (DDI). Section 6: Efavirenz drug-drug interactions
(DDI). Section 7: System-dependent parameters.
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